Fundamentals of Nuclear Pharmacy, 5th Edition by Gopal B. Saha (Springer-Verlag) Upon publication of the First Edition, Fundamentals of Nuclear Pharmacy emerged as the standard text and reference in nuclear medicine. Generously supplemented with charts, tables, and more than 100 illustrations, the revised Fifth Edition of this classic text has been thoroughly updated by judiciously replacing obsolete sections with new, cutting-edge material. Each chapter provides the reader with well-delineated descriptions of the subject matter from the basic atomic structure to the clinical uses of radiopharmaceuticals. Previous editions were highly acclaimed for their clarity and accuracy since Dr. Saha sets new standards for making complex theoretical concepts readily understandable for students and practitioners in nuclear pharmacy and nuclear medicine.
New to the Fifth Edition:
The fifth edition of this book has been prompted by its great appreciation in the nuclear medicine community and a constant demand for upgrading with all the new developments in radiopharmaceutical chemistry and clinical nu-clear medicine over the past 6 years. In the revision process, obsolete items have been replaced with new, up-to-date items.
The scope and contents of this edition are the same as those of the past editions. It serves as a textbook on nuclear chemistry and pharmacy for nuclear medicine residents and technologists as well as a reference book for many nuclear medicine physicians and radiologists.
The book has 16 chapters. At the end of each chapter, a set of questions and suggested reading materials related to the chapter are provided. As usual, Chapters 1 to 6 have only minor changes because the basic nature of the subject matter does not change over time. Some minor changes in Chapter 4 reflect the addition of newer equipment. Chapter 7 has been extensively revised by deleting clinically obsolete radiopharmaceuticals and adding new ones. A section on positron emission tomography (PET) radio-pharmaceuticals has been added in this chapter. Chapters 8 to 10 do not have any major changes except updated information, a new absorbed dose list in Table 10.2, and a new section on effective doses in Chapter 10. Chapter 11 is thoroughly revised to include all new, up-to-date U.S. Food and Drug Administration and Nuclear Regulatory Commission regulations and guidelines. A section on European Regulations has been added to the chapter. No revisions have has been made in Chapter 12. Many changes have been made in Chapter 13 by removing obsolete imaging agents and adding new ones for different organs. Currently, molecular imaging has be-come the prime topic of interest in imaging modalities, and so a new chap-ter, Chapter 14, has been added to briefly discuss the subject. The former Chapter 14 has become Chapter 15 with the addition of a new therapeutic radiopharmaceutical. Adverse reactions and iatrogenic alterations in the biodistribution of radiopharmaceuticals are presented in Chapter 16 without any change.
Biotechnology and Biopharmaceuticals: Transforming Proteins and Genes into
Drugs by Rodney J. Ho, Milo Gibaldi (Wiley-Liss) defines
biotechnology from the perspective of pharmaceuticals. The first section focuses
on the process of transforming a biologic macromolecule into a therapeutic
agent, while the second section provides a brief overview of each class of
macromolecule with respect to physiological role and clinical application.
Additional detail is also provided in the second section for each FDA approved,
recombinantly derived biopharmaceutical for each category of macromolecule. The
final section looks to the future and the new advances that will enhance our
ability to develop new macromolecules into effective biopharmaceuticals. This
last section discusses various drug delivery strategies while also describing
gene and cell therapy strategies.
The list of
biotechnology-based therapeutics has rapidly grown since 1982 when FDA approved
the first recombinant biotech drug, insulin, for human use. The annual sales of
several protein therapeutics have surpassed the billion dollar mark. With the
completion of the primary DNA map for the human genome and the progress made in
high-throughput technology for drug discovery, we are about to experience an
explosive, never-before-seen growth in the development of therapeutic
modalities. Biotechnology, the application of biologic molecules to mimic
biologic processes, will play a central role in the discovery and development
of protein- and gene-based drugs. While there are books discussing various
aspects of biotechnology, there is no single, comprehensive source of
information available for pharmaceutical scientists and health care
principles of pharmacology and pharmaceutics have helped us to understand the
relationship between clinical outcomes and the physical-chemical properties of
traditional drugs and dosage forms. These principles, however, often fail to
accommodate the products of biotechnology. The therapeutic application of
protein-based drugs over the past 10 years has provided a much fuller
understanding of the intricacies and mechanisms of protein disposition and
pharmacologic actions. To fully appreciate the complexities of these
macromolecules and their biologic effects, one must understand the fundamental
differences in drug design, dosage formulation, and time course of
distribution, to target tissues between proteinbased drugs and small organic
molecules. New strategies have been developed to deliver protein-based drugs and
more will follow.
undertook the considerable task of creating this book because we believe
established pharmaceutical scientists, as well as those in training, need to
understand the principles underlying the discovery, development, and
application of drugs of the future. An understanding and appreciation of these
principles by health scientists, physicians, pharmacists, and other health care
providers should allow informed decisions to improve the pharmaceutical care
of patients. The ability to integrate this knowledge in the clinical setting is
essential, especially for the clinical pharmacologist and pharmacist. We also
believe that a single source of comprehensive information about biotechnology
is needed to serve the interests of a large population of professionals. This
book considers biotechnology products from the following perspectives: (1) the
integration of pharmacology and biotechnology with medical sciences, (2) the
unique aspects of the applications of biologics or macromolecules as
therapeutic agents, (3) the impact of biotechnology on modern medicine, and (4)
the prospect of applying cutting-edge biotechnology and drug systems in shaping
the future of medical practice.
focuses on the process of taking a biologic macromolecule such as a protein
found naturally in minute quantities from identification of structure and
function to a therapeutic agent that can be delivered safely and effectively in
a pharmaceutical dosage form to patients for a specific therapeutic indication.
With the advancement of recombinant DNA technology and the enhancements in
automation efficiency and computing power, we have more drug targets than we can
exploit to produce, recombinantly or synthetically, drugs or pharmaceuticals
that provide health benefits. Therefore it is increasingly important for drug
industry decision makers, pharmaceutical scientists, and physicians to acquire
the knowledge that has been gained from the experience of transforming biologic
macromolecules into drugs. The first part of the book highlights some of the key
differences between the discovery and development of small molecules and
familiar with biotechnology, biopharmaceutics, and the drug development
process, and for those that focus on the application of biopharmaceuticals, Part
II provides a brief overview of each class of macromolecule with respect to
physiological role and clinical application. Additional detail for each FDA
approved, recombinantly derived biopharmaceutical, and several other interesting
therapeutic proteins, for each category of macromolecule is provided in
monographs. These monographs are organized as follows: (1) general description,
(2) indications, (3) dosage form, route of administration, and dosage, (4)
pharmacology and pharmaceutics (i.e.., clinical pharmacology, pharmacokinetics,
disposition, and drug interactions), (5) therapeutic response, (6) role in
therapy, and (7) other clinical applications. Readers seeking pharmacokinetic
information and additional details on molecular characteristics of
biopharmaceuticals are directed to the appendices.
focuses on the future, on advances that will enhance our ability to develop new
and already identified macromolecules into safe and effective
biopharmaceuticals. Using drug delivery strategies to optimize drug
distribution profiles, including drug targeting by means of physical-chemical
and physiological approaches, as well as optimization of molecular properties
by sequence modification and molecular redesign are key strategies needed to
improve safety and efficacy and to increase the limited bioavailability of
macromolecules that often requires systemic or regional administration. This
part also describes gene and cell therapies, strategies that are needed when
traditional drug therapy is not suitable or effective.
drugs that produce severe toxicity in a small population of patients but are
otherwise safe and effective for the majority of patients, laboratory-based
genetic tests are in development to identify the at-risk population. As our
understanding of the relationship between phamacological responses and genetic
variations grows, it is important to learn how pharmacogenetic and other factors
may allow pharmacists and physicians to consider the cost and benefits of
individualized drug selection and dosage regimens. With automation of
analytical, robotic, and computational techniques, the role of proteomics and
genomics in accelerating drug discovery and predicting pharmacophores and
perhaps pharmacokinetic properties may allow scientist to reduce to a minimum
the number of candidate molecules needed to be synthesized or cloned. Some of
these efforts have allowed the chemical synthesis of active-site mimics that are
similar to classic drugs.
concludes with a chapter on how these scientific advances are being integrated
by large and small biotechnologydriven and traditional drug companies to
accelerate the drug discovery and development processes. The pharmaceutical
industry is nearly universally incorporating biotech strategies as tools to
accelerate the development of drug from concepts into products.
Smith and Williams’ Introduction to the Principles of Drug Design and Action edited by H. John Smith (Hardwood Academic Publishers) The second edition of Introduction to the Principles of Drug Design was published in 1988. In the intervening years considerable strides have been made in the approaches to rational drug design as the result of the flood of knowledge coming from advances made in molecular biology. This has provided a better understanding of biological systems in terms of their structural components, cellular signalling, genomic modulation etc., leading to a more informed approach to chemotherapeutic intervention in disease.
In the third edition the aims and objectives, as well as the intended reading audience, remain the same as in previous editions but all the chapters have been revised to take into account of new developments in their subject areas and three new chapters have been included. Chapter 4 dealing with Drug Chirality and its Pharmacological Consequences reviews an ongoing field of considerable importance to pharmacologists and especially industrial concerns in view of the recent requirements imposed by Regulatory Bodies regarding drug registration. Chapter 6 provides a fascinating account of the difficulties inherent in the development of a drug from the bench to the clinic and brings out the trials and tribulations encountered by the multi-disciplinary research teams involved. Chapter 10 on Neurotransmitters, Agonists and Antagonists compensates to some extent for an area neglected in previous editions, that is, the design of drugs for action on the central nervous system, and also provides an account of membrane-bound receptors perhaps overshadowed in previous editions by emphasis on enzyme and DNA related targets.Chapter 3 on Intermolecular Forces and Molecular Modelling has required expansion and revision due to advances in the techniques relating to ligand-receptor interactions and we are indebted to Zeneca, through Dr M.T. Cox, for their generosity in meeting the considerable cost of reproducing the necessary new colour plates in the book. We also wish to thank Dr Charlie Laughton of the School of Pharmacy, Nottingham University for providing the illustration on the front cover of the book.
insert content here